CN108129367A - 一种构建手性亚磺酰亚胺α位手性四级碳的构建方法及其产品与应用 - Google Patents
一种构建手性亚磺酰亚胺α位手性四级碳的构建方法及其产品与应用 Download PDFInfo
- Publication number
- CN108129367A CN108129367A CN201810111787.7A CN201810111787A CN108129367A CN 108129367 A CN108129367 A CN 108129367A CN 201810111787 A CN201810111787 A CN 201810111787A CN 108129367 A CN108129367 A CN 108129367A
- Authority
- CN
- China
- Prior art keywords
- compound
- chiral
- nmr
- reaction
- cdcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052799 carbon Inorganic materials 0.000 title claims abstract description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 238000010276 construction Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 57
- 238000006243 chemical reaction Methods 0.000 claims abstract description 38
- 238000005804 alkylation reaction Methods 0.000 claims abstract description 7
- 230000029936 alkylation Effects 0.000 claims abstract description 5
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 4
- 230000004761 fibrosis Effects 0.000 claims abstract description 4
- 210000000056 organ Anatomy 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 129
- 239000000047 product Substances 0.000 claims description 48
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 38
- 238000004440 column chromatography Methods 0.000 claims description 38
- 239000007858 starting material Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 26
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 17
- -1 heterocyclic arene Chemical class 0.000 claims description 14
- 238000012805 post-processing Methods 0.000 claims description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000012074 organic phase Substances 0.000 claims description 8
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims description 8
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 229940126062 Compound A Drugs 0.000 claims description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 6
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 claims description 6
- 238000010791 quenching Methods 0.000 claims description 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- 125000005741 alkyl alkenyl group Chemical group 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 4
- 125000000468 ketone group Chemical group 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 3
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002585 base Substances 0.000 claims 7
- 239000003513 alkali Substances 0.000 claims 6
- 239000000463 material Substances 0.000 claims 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 230000000171 quenching effect Effects 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- QAZLUNIWYYOJPC-UHFFFAOYSA-M sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 75
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 70
- 239000011734 sodium Substances 0.000 description 40
- 238000003786 synthesis reaction Methods 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 38
- 239000012039 electrophile Substances 0.000 description 36
- 239000012043 crude product Substances 0.000 description 35
- 239000003208 petroleum Substances 0.000 description 35
- 229940125898 compound 5 Drugs 0.000 description 33
- 238000011282 treatment Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 6
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 6
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- 0 CC(C)(C)[S-](C)N=C(CCCCC1)[C@]1(C*1ccc(*)cc1)C(CCC=C)=N Chemical compound CC(C)(C)[S-](C)N=C(CCCCC1)[C@]1(C*1ccc(*)cc1)C(CCC=C)=N 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 4
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 3
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 3
- 102100032442 Protein S100-A8 Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 150000001728 carbonyl compounds Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- LZIYAIRGDHSVED-UHFFFAOYSA-N 1-(bromomethyl)-3-chlorobenzene Chemical compound ClC1=CC=CC(CBr)=C1 LZIYAIRGDHSVED-UHFFFAOYSA-N 0.000 description 2
- FWLWTILKTABGKQ-UHFFFAOYSA-N 1-(bromomethyl)-3-methylbenzene Chemical compound CC1=CC=CC(CBr)=C1 FWLWTILKTABGKQ-UHFFFAOYSA-N 0.000 description 2
- IKSNDOVDVVPSMA-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C=C1 IKSNDOVDVVPSMA-UHFFFAOYSA-N 0.000 description 2
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 2
- LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical compound CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 2
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000005555 sulfoximide group Chemical group 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- XKVLZBNEPALHIO-UHFFFAOYSA-N 1-bromo-2-methylbutane Chemical compound CCC(C)CBr XKVLZBNEPALHIO-UHFFFAOYSA-N 0.000 description 1
- BUZZUHJODKQYTF-UHFFFAOYSA-N 1-iodo-3-methylbutane Chemical compound CC(C)CCI BUZZUHJODKQYTF-UHFFFAOYSA-N 0.000 description 1
- RUHJZSZTSCSTCC-UHFFFAOYSA-N 2-(bromomethyl)naphthalene Chemical compound C1=CC=CC2=CC(CBr)=CC=C21 RUHJZSZTSCSTCC-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- LNTIKAHDNWYAGL-UHFFFAOYSA-N Br.CC#C Chemical compound Br.CC#C LNTIKAHDNWYAGL-UHFFFAOYSA-N 0.000 description 1
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ketene group Chemical group C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/06—Sulfinamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供一种构建手性亚磺酰亚胺α位手性四级碳的烷基化方法及其产品与应用,烷基化方法反应原料廉价,反应条件温和,反应步骤简单、易于操作,区域选择性高,立体选择性高,并且以较高的收率得到一类之前方法难以得到的α位具有手性四级碳的手性亚磺酰亚胺衍生物,适用于工业化生产;而且,本发明提供的α位具有手性四级碳的手性亚磺酰亚胺具有较好的抑制器官纤维化作用,对国民经济和社会发展及人民健康等都将具有重要的理论价值和实际意义,具有很好的应用前景。
Description
技术领域
本发明属于有机合成领域,涉及手性亚磺酰亚胺α位手性四级碳的烷基化方法,以及由该合成方法制得的α位具有手性四级碳的手性亚磺酰亚胺类产品。
背景技术
羰基化合物的α位官能团化可构建大量天然产物及药物分子的结构单元。借助手性辅基手性亚磺酰胺来实现羰基化合物的α位不对称官能团化是一种易分离、具有规模化生产潜力的新兴方法。但目前报道的手性磺亚胺的烷基化方法条件一般较为苛刻,而且往往会产生多取代和消除副产物。
此外,手性四级碳的构建也是目前合成界的一大难题。现有技术也提供了一些四级碳的合成方法,如中国专利CN107188874A提供了一种利用Michael加成反应构建手性四级碳的方法,该方法利用B-不饱和烯酮位原料,通过手性催化剂控制手性进行Michael加成反应,成功得到了具有手性四级碳中心的目标产物,但该方法需要用到的手性催化剂难以合成或较为昂贵;又如CN104744394B披露了一种Ni催化的不对称反应,构建了一类具有三氟甲基的手性四级碳中心的化合物,但该方法同样需要使用到昂贵的手性配体,且金属催化一般对空气及空气中的水分比较敏感,不利于放大规模生产。因此,研发出一种条件温和、反应步骤简单、易于操作、区域选择性高、立体选择性高的高效手性四级碳构建方法,是本领域研发人员当前的研究重点之一。
发明内容
为了克服上述现有技术中存在的缺陷与不足,本发明旨在利用手性辅基叔丁基亚磺酰胺及吸电子导向基团的协同作用,提供一种简单、高区域选择性和立体选择性的亚胺及酮类化合物α位四级碳手性中心的构建方法。其合成路线如下:
并且,所述方法包括以下步骤:
(1)以羰基化合物A1为起始原料,与手性亚磺酰胺缩合,制得中间体A2;
(2)所述中间体A2与氯甲酸烯丙酯等导向基团供体反应制得中间体A3;
(3)所述中间体A3经烷基化反应,即制得α位具有手性四级碳的手性亚磺酰亚胺A。
根据上述合成方法,可制备的化合物的结构通式包括环状结构通式I:
并且,所述结构通式I具有以下特点:
(I1)导向基团DG可为多种吸电子基团:包括酯基、酮基、酰胺基、氰基、硝基等;
(I2)亲电取代基R可为;烷基芳基、烷基烯基、烷基炔基、烷基、F、CF3、Br、Cl以及Michael受体;
(I3)B环可为C4-C30的碳环,C4-C30的含氮、硫、氧、磷等碳杂环;
(I4)化合物中叔丁基(t-Bu)可以是2,4,6-三甲基苯基(Mes)、甲基苯基(Tol)、苯基(Ph)以及异丙基(i-pr)等,亚磺酰基的构型可以是R、S。
根据上述合成方法,可制备的化合物的结构通式包括环状结构通式II:
并且,所述结构通式II具有以下特点:
(II1)导向基团DG可为多种吸电子基团:包括酯基、酮基、酰胺基、氰基、硝基等;
(II2)取代基R可为;烷基芳基、烷基烯基、烷基炔基、烷基;
(II3)R1和R2各自独立地选自:H,C1-C30的链烷基,C3-C30的环丙烷基,C2-C30的链烯基,C3-C30的环烯基,C2-C30的链炔基,C1-C30的烷氧基,C7-C30芳烃基烷氧基,C6-C30的芳烃基,C4-C30的杂环芳烃基。
(II4)化合物中叔丁基(t-Bu)可以是2,4,6-三甲基苯基(Mes)、甲基苯基(Tol)、苯基(Ph)以及异丙基(i-pr)等,亚磺酰基的构型可以是R、S。
优选地,通式I、II中:
(1)导向基团DG可优选为:烯丙氧羰基、苄氧羰基、异丙氧羰基、甲氧羰基;
(2)取代基R可优选为苄基、取代苄基、烯丙基、取代烯丙基、炔丙基、取代炔丙基以及饱和烷烃;
优选地,所述化合物合成方法包括以下步骤:
(1)将化合物A1溶于四氢呋喃中,依次加入R-叔丁基亚磺酰胺、四异丙醇钛反应,后处理,制得中间体A2;
(2)将所述中间体A2溶于四氢呋喃中,冷却至-78℃,加入碱B1反应,再加入氯甲酸烯丙酯等导向基团供体,-78℃下搅拌反应,后处理,制得中间体A3;
(3)将所述中间体A3溶于四氢呋喃中,冷却至0℃,加入碱B2反应,再加入亲电试剂(R-X)反应,后处理,制得目标产物A。
优选地,在上述合成方法中,步骤(1)为:
将化合物A1溶于四氢呋喃中,在室温下依次加入R-叔丁基亚磺酰胺、四异丙醇钛,加热至40-70℃反应6-12小时,后处理,制得中间体A2;
优选地,在上述合成方法中,步骤(2)为:
将所述中间体A2溶于四氢呋喃中,在低温反应仪下冷却至-78℃,加入碱B1反应1小时,再缓慢滴加氯甲酸烯丙酯等导向基团供体,-78℃下搅拌反应2-5小时,后处理,制得中间体A3;
优选地,所述碱B1可优选为NaHMDS、KHMDS、LiHMDS;
优选地,在上述合成方法中,步骤(3)为:
将所述中间体A3溶于四氢呋喃中,冷却至0℃,加入碱B2反应15分钟,0℃下搅拌反应15-60分钟,再加入亲电试剂(R-X),反应5-60分钟后移至20-60℃下反应8-24小时,后处理,制得目标产物A;
优选地,所述碱B2可优选为NaHMDS、KHMDS、LiHMDS。
另外,在上述合成方法中,各反应步骤(1)~(4)中所述的“后处理”均为本领域技术人员根据本步反应条件做出的合适的后处理,这些后处理旨在除去杂质与溶剂并在一定程度上保证获得纯净的产物。
可选地,步骤(1)中的后处理指的是:反应完毕后,向反应液中加入水猝灭,过滤除去沉淀,并用乙酸乙酯洗涤沉淀,所得有机相经无水硫酸钠干燥,抽滤、浓缩后用快速柱层析分离,即得中间体A2。
可选地,步骤(2)中的后处理指的是:反应完毕后,向反应液中加入饱和氯化铵溶液猝灭,并用乙酸乙酯萃取3次,合并有机相经无水硫酸钠干燥,抽滤、浓缩后用快速柱层析分离,即得中间体A3。
可选地,步骤(3)中的后处理指的是:反应完毕后,向反应液中加入饱和氯化铵溶液猝灭,并用乙酸乙酯萃取3次,合并有机相经无水硫酸钠干燥,抽滤、浓缩后用快速柱层析分离,即得目标产物A。
本发明还提供一种上述化合物A在制备抑制器官纤维化药物中的应用。
一种药物组合物,其含有效治疗量的所述的化合物A,以及药学上接受的辅料;
优选的,所述药物组合物为片剂、胶囊剂、气雾剂、分散片、口服液、栓剂、滴丸剂、大输液、小针、冻干粉针、软膏或搽剂等剂型药物,包括采用现已公认的药剂学常识常规制备而得的各种缓释、控释剂型或纳米制剂。
本发明所提供的烷基化方法反应原料廉价,反应条件温和,反应步骤简单、易于操作,区域选择性高,立体选择性高,并且以较高的收率得到一类之前方法难以得到的α位具有手性四级碳的手性亚磺酰亚胺衍生物,适用于工业化生产;而且,本发明提供的α位具有手性四级碳的手性亚磺酰亚胺具有较好的抑制器官纤维化作用,对国民经济和社会发展及人民健康等都将具有重要的理论价值和实际意义,具有很好的应用前景。
附图说明
构成本发明的一部分的附图用来提供对本发明的进一步理解,本发明的示意性实施例及其说明用于解释本发明,并不构成对本发明的不当限定。在附图中:
图1为本发明实施例20核磁数据(NMR Spectrums of Compounds);
图2分别为本发明实施例21核磁数据。
具体实施方式
除非另外说明,本文中所用的术语均具有本领域技术人员常规理解的含义,为了便于理解本发明,将本文中使用的一些术语进行了下述定义。
在说明书和权利要求书中使用的,单数型“一个”和“这个”包括复数参考,除非上下文另有清楚的表述。例如,术语“(一个)细胞”包括复数的细胞,包括其混合物。
所有的数字标识,例如pH、温度、时间、浓度,包括范围,都是近似值。要了解,虽然不总是明确的叙述所有的数字标识之前都加上术语“约”。同时也要了解,虽然不总是明确的叙述,本文中描述的试剂仅仅是示例,其等价物是本领域已知的。
本发明的第一方面,提供了一种α位具有手性四级碳的手性亚磺酰亚胺衍生物的合成方法,其合成路线如下:
并且,所述合成方法包括以下步骤:
(1)将化合物A1溶于四氢呋喃中,依次加入R-叔丁基亚磺酰胺、四异丙醇钛反应。后处理,制得中间体A2;
(2)将所述中间体A2溶于四氢呋喃中,冷却至-78℃,加入NaHMDS或KHMDS反应,再加入氯甲酸烯丙酯等导向基团供体,-78℃下搅拌反应,后处理,制得中间体A3;
(3)将所述中间体A3溶于四氢呋喃中,冷却至0℃,加入NaHMDS或KHMDS反应,再加入亲电试剂(R-X)反应,后处理,制得目标产物A4。
本发明的第二方面,提供了一种α位具有手性四级碳的手性亚磺酰亚胺衍生物,该α位具有手性四级碳的手性亚磺酰亚胺衍生物是根据本发明第一方面所述的合成方法制得的目标产物A。
实例1:关键中间体1的合成
操作步骤:在氩气保护下,向圆底烧瓶中加入磺亚胺(30mmol),加入四氢呋喃(150mL)溶解,在低温反应器下冷却至-78℃。滴加NaHMDS(30mL,2M in THF),反应1小时后滴加氯甲酸烯丙酯(60mmol)。继续在-78℃反应3小时。待TLC监测反应完全,用饱和NH4Cl(100mL)溶液淬灭,用乙酸乙酯萃取三次(3x 100mL)。收集有机相用无水硫酸钠(Na2SO4)干燥,过滤后用旋转蒸发仪旋干。粗品用柱层析分离(石油醚:乙酸乙酯=5:1)即得目标产物1。
8.5g;产率:95%;浅黄色油状物;[α]D 23=-24.67(c 1.0,CHCl3).IR(KBr)νmax:2962,2864,1659,1602,1260,1229,1097,1039,1031,1001,801cm-1.1H NMR(400MHz,CDCl3)δ10.91(s,1H),6.00–5.87(m,1H),5.25(dd,J=33.6,13.7Hz,2H),4.60(s,2H),2.77(m,2H),2.49(m,2H),1.83–1.58(m,4H),1.46(m,2H),1.31(s,9H).13C NMR(100MHz,CDCl3)δ169.9,161.6,132.7,117.6,105.7,64.8,56.8,31.8,30.5,26.9,26.1,24.9,22.8.HRMS(ESI)calculated for C15H25NNaO3S+[M+Na]+:322.1447,found 322.1443.
实例2:关键中间体2的合成(制备方法同关键中间体1的合成)
7.6g;产率:93%;浅黄色油状物;[α]D 23=-54.69(c 0.5,CHCl3).IR(KBr)νmax:2949,2863,1653,1600,1230,1229,1088,1055,803cm-1.1H NMR(400MHz,CDCl3)δ9.17(s,1H),6.15–5.62(m,1H),5.23(ddd,J=13.8,11.5,1.2Hz,2H),4.60(m,2H),2.87(dd,J=16.4,8.3Hz,1H),2.66(dd,J=16.7,8.6Hz,1H),2.60–2.46(m,2H),1.95–1.84(m,2H),1.27(s,9H).13C NMR(100MHz,CDCl3)δ167.4,158.2,132.6,117.8,103.6,64.3,56.8,32.6,29.2,22.4,20.6.HRMS(ESI)calculated for C13H21NNaO3S+[M+Na]+:294.1134,found294.1131.
实例3:关键中间体3的合成(制备方法同关键中间体1的合成)
8.0g;产率:93%;浅黄色油状物;[α]D 20=-28.41(c 0.5,CHCl3).IR(KBr)νmax:2959,2865,1662,1598,1259,1231,1088,1055,1021,804cm-1.1H NMR(400MHz,CDCl3)δ10.72(s,1H),5.94(ddd,J=22.6,10.6,5.4Hz,1H),5.27(ddd,J=13.8,11.8,1.4Hz,2H),4.66–4.57(m,2H),2.72(dt,J=11.1,6.2Hz,1H),2.48(dt,J=17.9,6.2Hz,1H),2.34(dt,J=11.2,5.4Hz,2H),1.82–1.61(m,4H),1.32(s,9H).13C NMR(100MHz,CDCl3)δ170.0,154.0,132.6,117.7,100.9,64.7,56.6,27.3,24.0,22.8,22.3,22.0.HRMS(ESI)calculated forC14H23NNaO3S+[M+Na]+:308.1291,found 308.1290.
实例4:关键中间体4的合成(制备方法同关键中间体1的合成)
8.6g;产率:92%;浅黄色油状物;[α]D 27=-11.62(c 1.0,CHCl3).IR(KBr)νmax:2963,2870,1659,1589,1453,1230,1097,1054,1019,803cm-1.1H NMR(400MHz,CDCl3)δ10.91(s,1H),5.88(ddd,J=16.8,10.5,5.3Hz,1H),5.24(dd,J=17.2,1.4Hz,1H),5.14(dd,J=10.5,1.3Hz,1H),4.76–4.44(m,2H),2.88–2.67(m,2H),2.49–2.30(m,2H),1.79(m,1H),1.61–1.39(m,7H),1.26(s,9H).13C NMR(100MHz,CDCl3)δ170.0,157.8,132.7,117.4,103.0,64.6,56.8,30.4,29.3,28.3,26.8,26.3,25.9,22.8.HRMS(ESI)calculated forC16H27NNaO3S+[M+Na]+:336.1604,found 336.1602.
实例5:化合物5的合成
操作步骤:在氩气保护下,向圆底烧瓶中加入化合物1(0.10g,0.33mmol),加入四氢呋喃(1mL),在冰浴下冷却至0℃,滴加NaHMDS(0.25mL,2M in THF)。反应15分钟后滴加苄溴(BnBr)。反应在室温下过夜,待TLC监测反应完全后用饱和NH4Cl(10mL)溶液淬灭,用乙酸乙酯萃取三次(3x 10mL)。合并有机相用无水硫酸钠(Na2SO4)干燥,过滤后用旋转蒸发仪旋干。粗品用柱层析分离(石油醚:乙酸乙酯=5:1)即得无色油状产物5(105mg,产率:82%):[α]D 20=-140.54(c 2.0,CHCl3).IR(KBr)νmax:2931,2862,1733,1618,1453,1192,1080,933,739,703cm-1.1`1H NMR(400MHz,CDCl3)δ7.24(ddd,J=9.1,6.5,2.6Hz,3H),7.12–7.06(m,2H),5.90(ddt,J=16.4,10.5,5.9Hz,1H),5.29(ddd,J=13.8,11.5,1.2Hz,2H),4.64(dd,J=13.1,5.8Hz,1H),4.56(dd,J=13.1,5.9Hz,1H),3.38(d,J=13.7Hz,1H),3.01–2.90(m,2H),2.60(ddd,J=12.6,10.0,3.0Hz,1H),2.00(dd,J=14.0,8.8Hz,1H),1.78(m,4H),1.62(m,1H),1.53–1.44(m,2H),1.30(s,9H).13C NMR(100MHz,CDCl3)δ185.2,172.6,137.1,131.8,130.6,128.3,126.9,119.1,66.1,63.0,58.2,42.2,32.9,32.0,29.9,26.3,23.7,23.0.HRMS(ESI)calculated for C22H31NNaO3S+[M+Na]+:412.1917,found 412.1915.
实例6:化合物6的合成
使用化合物5操作步骤,原料1(0.10g,0.33mmol)与亲电试剂4-硝基苄基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=3:1)得到浅黄色油状产物6(132mg,产率:92%):[α]D 20=-100.65(c 2.0,CHCl3).IR(KBr)νmax:2959,2930,2860,1734,1622,1605,1521,1456,1346,1261,1174,1080,994,856,802,741,701cm-1.1H NMR(400MHz,CDCl3)δ8.12(d,J=7.6Hz,2H),7.28(d,J=7.7Hz,2H),5.89(dq,J=11.0,5.8Hz,1H),5.31(dd,J=21.7,13.8Hz,2H),4.65(dd,J=12.4,4.4Hz,1H),4.57(dd,J=12.4,5.3Hz,1H),3.47(d,J=13.6Hz,1H),3.09(dd,J=20.2,12.2Hz,2H),2.62(t,J=11.0Hz,1H),2.09–2.00(m,1H),1.85–1.65(m,5H),1.51(dd,J=22.1,12.1Hz,2H),1.29(s,9H).13C NMR(100MHz,CDCl3)δ184.1,172.0,147.0,145.3,131.5,131.4,123.4,119.6,66.4,62.9,58.4,41.7,32.6,32.4,29.8,26.3,23.7,22.9.HRMS(ESI)calculated forC22H30N2NaO5S+[M+Na]+:457.1768,found 457.1767.
实例7:化合物7的合成
使用化合物5操作步骤,原料1(0.10g,0.33mmol)与亲电试剂4-三氟甲基苄基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=6:1)得到浅黄色油状产物7(139mg,产率:92%):[α]D 20=-97.23(c 1.0,CHCl3).IR(KBr)νmax:2958,2933,2860,1731,1620,1601,1519,1454,1350,1260,1180,1083,993,853,801,744,701cm-1.1H NMR(400MHz,CDCl3)δ7.50(d,J=7.0Hz,2H),7.21(d,J=7.1Hz,2H),5.94–5.82(m,1H),5.29(dd,J=23.0,13.7Hz,2H),4.64(dd,J=13.0Hz,1H),4.55(dd,J=13.1Hz,1H),3.42(d,J=13.5Hz,1H),3.02(t,J=11.8Hz,2H),2.61(t,J=10.9Hz,1H),2.01(d,J=11.6Hz,1H),1.74(m,5H),1.50(d,J=11.5Hz,2H),1.29(s,9H).13C NMR(100MHz,CDCl3)δ184.5,172.2,141.5,131.5,130.9,125.2,125.2,119.4,66.3,62.9,58.3,41.8,32.7,32.2,29.9,26.3,23.7,22.9.HRMS(ESI)calculated for C23H30F3NNaO3S+[M+Na]+:480.1791,found 480.1788.
实例8:化合物8的合成
使用化合物5操作步骤,原料1(0.10g,0.33mmol)与亲电试剂3-甲基苄基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=5:1)得到无色油状产物8(118mg,产率:89%):[α]D 20=-102.82(c 1.0,CHCl3).IR(KBr)νmax:2928,2861,1735,1620,1456,1389,1261,1231,1195,1175,1146,1081,1037,992,933,796,703cm-1.1H NMR(400MHz,CDCl3)δ7.14(t,J=7.2Hz,1H),7.02(d,J=7.4Hz,1H),6.88(d,J=9.1Hz,2H),5.96–5.84(m,1H),5.29(dd,J=29.4,13.8Hz,2H),4.60(qd,J=13.1,5.7Hz,2H),3.34(d,J=13.6Hz,1H),2.94(dd,J=23.2,12.7Hz,2H),2.58(t,J=11.1Hz,1H),2.30(s,3H),2.01(dd,J=22.7,9.0Hz,1H),1.87–1.70(m,4H),1.62(m,1H),1.54–1.45(m,2H),1.30(s,9H).13C NMR(100MHz,CDCl3)δ185.3,172.6,137.8,137.0,131.8,131.4,128.2,127.6,127.6,119.1,66.1,63.0,58.2,42.1,32.9,31.9,29.9,26.3,23.7,23.0,21.5.HRMS(ESI)calculated for C23H33NNaO3S+[M+Na]+:426.2073,found 426.2070.
实例9:化合物9的合成
使用化合物5操作步骤,原料1(0.10g,0.33mmol)与亲电试剂3-氯苄基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=5:1)得到无色油状产物9(126mg,产率:90%):[α]D 20=-104.62(c 1.0,CHCl3).IR(KBr)νmax:2959,2930,2862,1735,1621,1597,1572,1475,1456,1261,1231,1197,1173,1146,1081,1023,994,876,703,686cm-1.1H NMR(400MHz,CDCl3)δ7.18(d,J=4.9Hz,2H),7.09(s,1H),6.96(d,J=6.0Hz,1H),5.89(dq,J=10.3,6.0Hz,1H),5.30(dd,J=25.7,13.8Hz,2H),4.59(qd,J=12.9,5.8Hz,2H),3.35(d,J=13.7Hz,1H),3.10–3.02(m,1H),2.90(d,J=13.8Hz,1H),2.57(t,J=11.1Hz,1H),2.06–1.97(m,1H),1.85–1.70(m,4H),1.63–1.43(m,3H),1.29(s,9H).13C NMR(100MHz,CDCl3)δ184.6,172.2,139.3,134.1,131.6,130.7,129.5,128.8,127.1,119.6,66.3,63.0,58.3,41.6,32.7,32.0,29.9,26.3,23.6,23.0.HRMS(ESI)calculated for C22H30ClNNaO3S+[M+Na]+:446.1527,found 446.1523.
实例10:化合物10的合成
使用化合物5操作步骤,原料1(0.10g,0.33mmol)与亲电试剂烯丙基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=5:1)得到无色油状产物10(101mg,产率:90%):[α]D 20=-182.74(c 1.0,CHCl3).IR(KBr)νmax:2928,2859,1735,1620,1456,1361,1261,1198,1081,1020,919,802cm-1.1H NMR(400MHz,CDCl3)δ5.87(ddt,J=16.3,10.5,5.8Hz,1H),5.79–5.68(m,1H),5.26(ddd,J=13.8,11.6,1.3Hz,2H),5.10–5.02(m,2H),4.61(dd,J=13.2,5.8Hz,1H),4.54(dd,J=13.2,5.8Hz,1H),3.17–3.09(m,1H),2.75(dd,J=13.9,6.7Hz,1H),2.62(ddd,J=12.7,9.6,3.3Hz,1H),2.38(dd,J=13.9,7.9Hz,1H),2.13(dd,J=13.3,9.2Hz,1H),1.85–1.70(m,4H),1.62–1.41(m,3H),1.26(s,9H).13C NMR(100MHz,CDCl3)δ185.1,172.8,134.0,131.9,118.9,118.8,65.9,61.8,58.1,41.2,33.1,32.9,30.1,26.5,24.1,22.9.HRMS(ESI)calculated for C18H29NNaO3S+[M+Na]+:362.1760,found362.1758.
实例11:化合物11的合成
使用化合物5操作步骤,原料1(0.10g,0.33mmol)与亲电试剂3-溴-2-甲基丙烯反应。粗品用柱层析分离(石油醚:乙酸乙酯=6:1)得到无色油状产物11(111mg,产率:95%):[α]D 23=-67.69(c 0.5,CHCl3).IR(KBr)νmax:2936,2862,1733,1621,1459,1360,1259,1203,1083,1021,918,801cm-1.1H NMR(400MHz,CDCl3)δ5.87(dq,J=10.7,5.9Hz,1H),5.26(dd,J=33.6,13.8Hz,2H),4.85(s,1H),4.68(s,1H),4.61(dd,J=13.1,5.8Hz,1H),4.52(dd,J=13.1,5.9Hz,1H),3.24–3.12(m,1H),2.85(d,J=14.0Hz,1H),2.60–2.50(m,1H),2.38(d,J=14.0Hz,1H),2.16(dd,J=14.8,9.3Hz,1H),1.87–1.71(m,4H),1.63(s,3H),1.61–1.49(m,2H),1.40(m,1H),1.26(s,9H).13C NMR(100MHz,CDCl3)δ184.8,173.0,141.9,131.7,119.1,115.9,66.1,61.4,58.2,43.8,32.2,31.7,30.0,26.5,23.7,23.0.HRMS(ESI)calculated for C19H31NNaO3S+[M+Na]+:376.1917,found 376.1916.
实例12:化合物12的合成
使用化合物5操作步骤,原料1(0.10g,0.33mmol)与亲电试剂1-溴-3-甲基-2-丁烯反应。粗品用柱层析分离(石油醚:乙酸乙酯=6:1)得到无色油状产物12(111mg,产率:92%):[α]D 27=-69.25(c 1.0,CHCl3).IR(KBr)νmax:2937,2866,1730,1618,1462,1359,1257,1201,1079,1019,921,801cm-1.1H NMR(400MHz,CDCl3)δ5.85(ddd,J=16.0,10.7,5.5Hz,1H),5.29(d,J=17.2Hz,1H),5.21(d,J=10.4Hz,1H),5.04(s,1H),4.56(ddd,J=33.0,13.1,5.4Hz,2H),3.20–3.05(m,1H),2.73–2.54(m,2H),2.35(dd,J=14.0,8.2Hz,1H),2.15–2.06(m,1H),1.73(d,J=12.3Hz,5H),1.63(m,7H),1.42(d,J=9.0Hz,1H),1.26(s,9H).13C NMR(100MHz,CDCl3)δ185.3,173.0,135.1,131.9,119.4,118.8,65.9,62.2,58.1,35.0,32.8,30.2,26.5,26.2,24.1,22.9,22.5,18.1.HRMS(ESI)calculated forC20H33NNaO3S+[M+Na]+:390.2073,found 390.2077.实例13:化合物13的合成
使用化合物5操作步骤,原料1(0.10g,0.33mmol)与亲电试剂溴丙炔反应。粗品用柱层析分离(石油醚:乙酸乙酯=6:1)得到无色油状产物13(106mg,产率:95%):[α]D 20=-198.40(c 1.0,CHCl3).IR(KBr)νmax:2928,2859,1737,1621,1455,1362,1260,1191,1151,1082,936,802,688,641cm-1.1H NMR(400MHz,CDCl3)δ5.86(dq,J=11.0,5.8Hz,1H),5.26(dd,J=36.2,13.8Hz,2H),4.66–4.60(dd,J=13.3,5.8Hz,1H),4.58-4.55(dd,J=13.3,5.8Hz,1H),3.41–3.30(m,1H),2.98(d,J=16.8Hz,1H),2.57–2.46(m,2H),2.29(dd,J=14.8,9.8Hz,1H),2.12(dd,J=14.7,9.6Hz,1H),2.00(s,1H),1.80(m,2H),1.66–1.53(m,2H),1.44–1.29(m,2H),1.25(s,9H).13C NMR(100MHz,CDCl3)δ183.5,171.6,131.6,118.9,80.7,71.3,66.3,61.3,58.3,32.3,32.3,30.1,26.3,26.1,23.8,22.9.HRMS(ESI)calculated for C18H27NNaO3S+[M+Na]+:360.1604,found 360.1601.
实例14:化合物14的合成
使用化合物5操作步骤,原料1(0.10g,0.33mmol)与亲电试剂1-溴-2-丁炔反应。粗品用柱层析分离(石油醚:乙酸乙酯=6:1)得到无色油状产物14(110mg,产率:95%):[α]D 20=-142.84(c 2.0,CHCl3).IR(KBr)νmax:2926,2860,1737,1621,1455,1361,1260,1192,1178,1082,994,932,802cm-1.1H NMR(400MHz,CDCl3)δ5.86(dq,J=10.7,5.7Hz,1H),5.25(dd,J=39.1,13.8Hz,2H),4.59(m,2H),3.29(dd,J=11.2,5.0Hz,1H),2.90(d,J=16.6Hz,1H),2.55–2.37(m,2H),2.23(dd,J=14.9,9.6Hz,1H),2.08(dd,J=14.8,9.7Hz,1H),1.82–1.72(m,6H),1.63–1.49(m,2H),1.41–1.31(m,1H),1.24(s,9H).13C NMR(100MHz,CDCl3)δ183.9,171.9,131.8,118.6,78.6,75.2,66.1,61.6,58.2,32.5,32.4,30.1,26.8,26.1,23.8,22.8,3.6.HRMS(ESI)calculated for C19H29NNaO3S+[M+Na]+:374.1760,found374.1759.
实例15:化合物15的合成
使用化合物5操作步骤,在50℃下,原料1(0.10g,0.33mmol)与亲电试剂碘丁烷反应。粗品用柱层析分离(石油醚:乙酸乙酯=6:1)得到无色油状产物15(105mg,产率:90%):[α]D 20=-287.27(c 0.5,CHCl3).IR(KBr)νmax:2962,2937,2860,1732,1649,1607,1456,1263,1200,1091,1019,801cm-1.1H NMR(400MHz,CDCl3)δ5.88(ddd,J=16.3,10.9,5.8Hz,1H),5.37–5.18(m,2H),4.61(dd,J=13.3,5.7Hz,1H),4.55(dd,J=13.3,5.8Hz,1H),3.05–2.93(m,1H),2.72(ddd,J=12.3,9.2,3.0Hz,1H),2.20(dd,J=14.1,8.9Hz,1H),1.97–1.79(m,2H),1.78–1.59(m,5H),1.49(dd,J=22.4,14.5Hz,2H),1.33–1.19(m,13H),0.88(t,J=7.0Hz,3H).13C NMR(100MHz,CDCl3)δ186.1,173.4,132.0,118.7,65.7,62.0,57.9,36.9,33.9,33.1,30.2,26.9,24.6,23.4,22.9,14.1.HRMS(ESI)calculated for C19H33NNaO3S+[M+Na]+:378.2073,found378.2076.
实例16:化合物16的合成
使用化合物5操作步骤,在50℃下,原料1(0.10g,0.33mmol)与亲电试剂碘代异戊烷反应。粗品用柱层析分离(石油醚:乙酸乙酯=6:1)得到无色油状产物16(110mg,产率:90%):[α]D 26=-55.64(c 2.0,CHCl3).IR(KBr)νmax:2960,2931,2862,1733,1638,1603,1455,1269,1203,1100,1022,802cm-1.1H NMR(400MHz,CDCl3)δ5.88(qd,J=10.9,5.7Hz,1H),5.26(dd,J=33.3,13.8Hz,2H),4.65–4.53(m,2H),2.98(t,J=10.3Hz,1H),2.72(t,J=10.6Hz,1H),2.19(dd,J=14.2,8.8Hz,1H),1.95(t,J=12.7Hz,1H),1.84(s,1H),1.72(m,3H),1.60(m,2H),1.54–1.42(m,3H),1.25(s,9H),1.22–1.15(m,1H),1.09–1.00(m,1H),0.86(d,J=6.5Hz,6H).13C NMR(100MHz,CDCl3)δ186.1,173.3,132.0,118.7,65.7,62.0,57.9,35.0,33.7,33.6,33.1,30.2,28.8,27.0,24.5,22.9,22.7.HRMS(ESI)calculatedfor C20H35NNaO3S+[M+Na]+:392.2230,found 392.2229.
实例17:化合物17的合成
使用化合物5操作步骤,在50℃下,原料1(0.10g,0.33mmol)与亲电试剂碘丁烷反应。粗品用柱层析分离(石油醚:乙酸乙酯=6:1)得到浅黄色油状产物17(115mg,产率:92%):[α]D 23=-260.69(c 1.0,CHCl3).IR(KBr)νmax:2930,2863,1733,1619,1456,1361,1254,1225,1166,1079,984,936cm-1.1H NMR(400MHz,CDCl3)δ5.88(dq,J=10.7,5.6Hz,1H),5.27(dd,J=30.0,13.8Hz,2H),4.62(dd,J=13.1,5.6Hz,1H),4.54(dd,J=13.2,5.7Hz,1H),3.52(s,1.5H),3.15(s,0.5H),2.97(t,J=10.0Hz,1H),2.76(t,J=10.0Hz,1H),2.20(dd,J=14.1,9.2Hz,1H),2.05(t,J=11.4Hz,1H),1.74(ddd,J=26.9,18.7,7.2Hz,8H),1.54(dd,J=14.1,7.3Hz,2H),1.25(s,9H).13C NMR(100MHz,CDCl3)δ185.6,173.0,131.8,119.0,65.9,61.4,58.0,45.4,38.1,34.6,34.1,33.1,30.2,28.8,28.1,27.1,24.6,22.9.HRMS(ESI)calculated for C18H30ClNNaO3S+[M+Na]+:398.1527,found398.1523.
实例18:化合物18的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂溴化苄反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物18(100mg,产率:75%):[α]D 23=-102.43(c 1.0,CHCl3).IR(KBr)νmax:3062,3029,1733,1640,1495,1474,1390,1263,1219,1146,1084,931,795,770,703cm-1.1H NMR(400MHz,CDCl3)δ7.26–7.18(m,3H),7.17–7.11(m,2H),5.89(ddt,J=17.1,10.4,5.9Hz,1H),5.28(ddq,J=24.0,10.4,1.3Hz,2H),4.58(ddt,J=5.9,4.6,1.3Hz,2H),3.32(d,J=13.7Hz,1H),3.16–3.04(m,2H),2.52(ddd,J=14.9,9.4,7.9Hz,1H),2.26(dt,J=12.7,6.4Hz,1H),1.89–1.74(m,2H),1.56–1.47(m,1H),1.29(s,9H).13C NMR(100MHz,CDCl3)δ188.5,172.1,137.2,131.8,130.4,128.4,126.9,119.1,66.3,62.8,58.4,40.9,33.4,31.9,22.9,22.7.HRMS(ESI)calculated forC20H27NNaO3S+[M+Na]+:384.1604,found384.1603.
实例19:化合物19的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂4-硝基苄基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=6:1)得到浅黄色油状产物19(123mg,产率:82%):[α]D 22=-59.22(c 0.5,CHCl3).IR(KBr)2960,2925,1732,1642,1604,1521,1347,1262,1052,858,660νmax:cm-1.1H NMR(400MHz,CDCl3)δ8.17–8.10(m,2H),7.35(d,J=8.7Hz,2H),5.87(ddt,J=16.3,10.4,6.0Hz,1H),5.29(ddq,J=16.6,10.4,1.3Hz,2H),4.58(ddt,J=6.1,3.6,1.3Hz,2H),3.45(d,J=13.7Hz,1H),3.23–3.03(m,2H),2.60(dt,J=19.8,8.1Hz,1H),2.36–2.23(m,1H),1.98–1.83(m,1H),1.77–1.64(m,2H),1.28(s,9H).13C NMR(100MHz,CDCl3)δ187.3,171.5,147.1,145.2,131.5,131.3,123.6,119.6,66.6,62.6,58.6,40.6,33.1,32.2,22.8,22.7.HRMS(ESI)calculated for C20H26N2NaO5S+[M+Na]+:429.1455,found429.1453.
实例20:化合物20的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂4-三氟甲基苄基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物20(143mg,产率:90%):[α]D 23=-80.43(c 1.0,CHCl3).IR(KBr)2961,2928,1733,1618,1583,1456,1418,1326,1164,1123,1068,993νmax:cm-1.1H NMR(400MHz,CDCl3)δ7.52(d,J=8.2Hz,2H),7.28(d,J=9.2Hz,2H),5.87(ddt,J=16.6,10.6,5.9Hz,1H),5.38–5.20(m,2H),4.58(dd,J=5.5,4.6Hz,2H),3.39(d,J=13.7Hz,1H),3.21–3.03(m,2H),2.57(dt,J=19.6,7.8Hz,1H),2.27(dt,J=17.4,5.6Hz,1H),1.89(m,1H),1.78–1.69(m,1H),1.63(ddd,J=15.1,10.4,6.2Hz,1H),1.28(s,9H).13C NMR(100MHz,CDCl3)δ187.7,171.8,141.4,131.6,130.8,125.4,125.4,125.3,125.3,125.2,119.4,66.4,62.7,58.5,40.6,33.2,32.1,22.8,22.7.HRMS(ESI)calculated for C21H26F3NNaO3S+[M+Na]+:452.1478,found 452.1477.
实例21:化合物21的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂2-溴甲基萘反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到浅黄色油状产物21(114mg,产率:75%):[α]D 23=-61.21(c 1.0,CHCl3).IR(KBr)2959,2925,1732,1640,1508,1455,1389,1256,1220,1146,1083,1016,931,821,773,650,584,477νmax:cm-1.1H NMR(400MHz,CDCl3)δ7.82–7.72(m,3H),7.62(s,1H),7.49–7.41(m,2H),7.28(dd,J=8.4,1.6Hz,1H),5.89(ddt,J=16.3,10.4,5.9Hz,1H),5.36–5.21(m,2H),4.59(dd,J=5.9,1.2Hz,2H),3.49(d,J=13.7Hz,1H),3.29(d,J=13.7Hz,1H),3.11(ddd,J=19.5,8.0,5.4Hz,1H),2.52(ddd,J=19.5,11.8,6.1Hz,1H),2.28(dd,J=11.3,5.4Hz,1H),1.89–1.77(m,2H),1.59–1.51(m,1H),1.31(d,J=1.9Hz,9H).NMR(400MHz,)δ188.5,172.1,134.8,133.4,132.4,131.8,129.2,128.6,127.9,127.8,127.7,126.2,125.8,119.2,66.3,63.0,58.4,41.0,33.4,32.0,22.9,22.8.HRMS(ESI)calculated for C24H29NNaO3S+[M+Na]+:434.1760,found434.1763.
实例22:化合物22的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂3-甲基苄溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物22(111mg,产率:80%):[α]D 23=-94.93(c 0.3,CHCl3).IR(KBr)νmax:1960,2925,2856,1731,1606,1456,1262,1086,1019,800cm-1.1H NMR(400MHz,CDCl3)δ7.14(t,J=7.5Hz,1H),7.02(d,J=7.5Hz,1H),6.98–6.90(m,2H),5.89(ddd,J=16.5,11.1,5.8Hz,1H),5.28(dd,J=28.0,13.8Hz,2H),4.57(d,J=5.7Hz,2H),3.28(d,J=13.6Hz,1H),3.14–3.03(m,2H),2.51(dt,J=19.4,7.8Hz,1H),2.30(s,3H),2.25(dd,J=12.3,6.7Hz,1H),1.89–1.74(m,2H),1.57–1.51(m,1H),1.29(s,9H).13C NMR(100MHz,CDCl3)δ188.6,172.2,137.9,137.1,131.8,131.3,128.3,127.7,127.4,119.1,66.3,62.9,58.3,40.9,33.4,31.9,22.9,22.7,21.6.HRMS(ESI)calculated for C21H29NNaO3S+[M+Na]+:398.1760,found 398.1757.
实例23:化合物23的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂3-氯苄溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到浅黄色油状产物23(117mg,产率:80%):[α]D 23=-104.25(c 0.5,CHCl3).IR(KBr)νmax:2959,2926,2867,1733,1641,1475,1455,1362,1260,1214,1164,1147,1083,996,932,788,705,684cm-1.1H NMR(400MHz,CDCl3)δ7.22–7.14(m,3H),7.03(d,J=6.2Hz,1H),5.93–5.82(m,1H),5.29(dd,J=23.9,13.8Hz,2H),4.57(d,J=5.9Hz,2H),3.31(d,J=13.7Hz,1H),3.10(ddd,J=24.7,16.6,11.1Hz,2H),2.55(dt,J=19.4,7.8Hz,1H),2.28(dt,J=12.6,6.2Hz,1H),1.94–1.83(m,1H),1.78–1.69(m,1H),1.32–1.20(m,10H).13C NMR(100MHz,CDCl3)δ187.9,171.8,139.3,134.2,131.6,130.6,129.6,128.6,127.2,119.4,66.4,62.7,58.4,40.5,33.3,32.1,22.8,22.7.HRMS(ESI)calculated for C20H26ClNNaO3S+[M+Na]+:418.1214,found 418.1210.
实例24:化合物24的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂烯丙基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物24(78mg,产率:68%):[α]D 23=-130.32(c 1.0,CHCl3).IR(KBr)νmax:2960,2936,1733,1641,1453,1366,1263,1201,1139,1067,1009,853,801cm-1.1H NMR(400MHz,CDCl3)δ5.86(ddt,J=17.1,10.4,5.8Hz,1H),5.78–5.66(m,1H),5.34–5.18(m,2H),5.12–5.03(m,2H),4.55(ddt,J=5.8,2.5,1.4Hz,2H),3.20–3.02(m,1H),2.79–2.61(m,2H),2.40(dd,J=13.9,7.5Hz,1H),2.33–2.23(m,1H),2.02–1.90(m,1H),1.89–1.77(m,2H),1.22(s,9H).13C NMR(100MHz,CDCl3)δ188.6,172.1,133.7,131.8,119.0,118.9,77.5,77.2,76.8,66.1,61.4,58.2,39.7,33.3,32.1,22.7,22.7.HRMS(ESI)calculated for C16H25NNaO3S+[M+Na]+:334.1447,found 334.1449.
实例25:化合物25的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂3-溴-2-甲基丙烯反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物25(108mg,产率:90%):[α]D 20=-148.68(c 1.0,CHCl3).IR(KBr)νmax:2962,2925,1731,1640,1474,1376,1261,1195,1148,1085,1019,931,863,801cm-1.1H NMR(400MHz,CDCl3)δ5.88(ddt,J=16.3,10.5,5.9Hz,1H),5.27(ddd,J=13.8,11.5,1.2Hz,2H),4.82(s,1H),4.70(s,1H),4.55(d,J=5.9Hz,2H),3.12(ddd,J=19.5,8.7,5.7Hz,1H),2.89(d,J=14.3Hz,1H),2.66(dt,J=19.5,7.7Hz,1H),2.44–2.32(m,2H),1.98–1.73(m,3H),1.65(s,3H),1.23(s,9H).13C NMR(101MHz,CDCl3)δ188.5,171.9,141.9,131.8,119.0,115.2,66.2,61.3,58.2,43.3,32.9,31.9,23.7,22.8,22.7.HRMS(ESI)calculated for C17H27NNaO3S+[M+Na]+:348.1604,found348.1601.
实例26:化合物26的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂1-溴-3-甲基-2-丁烯反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物26(107mg,产率:85%):[α]D 23=-134.43(c 1.0,CHCl3).IR(KBr)νmax:2963,2937,1733,1644,1484,1379,1271,1197,1153,1091,1019,937,866,802cm-1.1H NMR(400MHz,CDCl3)δ5.88(ddd,J=22.6,10.9,5.7Hz,1H),5.27(dd,J=31.1,13.8Hz,2H),5.06(t,J=7.3Hz,1H),4.56(t,J=5.3Hz,2H),3.11(ddd,J=19.4,8.7,6.2Hz,1H),2.68(dt,J=18.5,7.3Hz,2H),2.41(dd,J=14.4,7.5Hz,1H),2.33–2.23(m,1H),1.95(dd,J=14.2,6.9Hz,1H),1.85(dd,J=14.3,6.5Hz,1H),1.79(s,1H),1.69(s,3H),1.61(s,3H),1.24(s,9H).13C NMR(101MHz,CDCl3)δ188.9,172.5,135.3,131.9,119.3,118.8,66.1,62.0,58.2,33.9,33.4,32.2,26.1,22.9,22.8,18.2.HRMS(ESI)calculated for C18H29NNaO3S+[M+Na]+:362.1760,found 362.1761.
实例27:化合物27的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂3-溴丙炔反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物27(103mg,产率:90%):[α]D 20=-121.17(c 1.0,CHCl3).IR(KBr)νmax:2963,2927,1735,1642,1456,1363,1261,1225,1151,1085,1019,801cm-1.1H NMR(400MHz,CDCl3)δ5.95–5.84(m,1H),5.38–5.21(m,2H),4.60(td,J=5.8,1.2Hz,2H),3.29–3.13(m,1H),2.85(dt,J=5.2,2.6Hz,1H),2.78–2.63(m,2H),2.43–2.31(m,1H),2.17–1.96(m,4H),1.25(s,9H).13C NMR(100MHz,CDCl3)δ187.9,171.5,131.6,119.1,80.5,70.6,66.3,60.4,58.2,33.5,32.6,25.2,23.1,22.7.HRMS(ESI)calculated for C16H23NNaO3S+[M+Na]+:332.1291,found 332.1289.
实例28:化合物28的合成
使用化合物5操作步骤,原料2(0.10g,0.37mmol)与亲电试剂1-溴-2-丁炔反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物28(102mg,产率:85%):[α]D 20=-99.34(c 1.0,CHCl3).IR(KBr)νmax:2962,2922,1735,1642,1362,1261,1224,1087,1020,801cm-1.1H NMR(400MHz,CDCl3)δ5.87(ddd,J=17.0,11.0,5.8Hz,1H),5.26(dd,J=32.6,13.8Hz,2H),4.57(t,J=5.6Hz,2H),3.16(dt,J=13.8,6.6Hz,1H),2.79–2.60(m,3H),2.31(dt,J=12.1,6.1Hz,1H),2.13–1.94(m,3H),1.73(s,3H),1.22(s,9H).13C NMR(100MHz,CDCl3)δ188.4,171.8,131.7,118.9,77.9,75.1,66.2,60.8,58.2,33.7,32.7,25.6,23.1,22.7,3.6.HRMS(ESI)calculated for C17H25NNaO3S+[M+Na]+:346.1447,found346.1449.
实例29:化合物29的合成
使用化合物5操作步骤,在50℃下,原料2(0.10g,0.37mmol)与亲电试剂碘甲烷反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物29(90mg,产率:85%):[α]D 27=-74.6(c 1.0,CHCl3).IR(KBr)νmax:2962,2927,2857,1731,1641,1455,1267,1089,801cm-1.1H NMR(400MHz,CDCl3)δ5.88(ddd,J=22.7,10.8,5.7Hz,1H),5.33–5.21(m,2H),4.57(ddd,J=33.8,13.1,5.7Hz,2H),3.12–3.00(m,1H),2.91–2.78(m,1H),2.41–2.30(m,1H),2.04–1.82(m,2H),1.70(dt,J=13.2,6.7Hz,1H),1.38(s,3H),1.23(s,9H).13C NMR(151MHz,CDCl3)δ190.0,173.5,131.9,118.8,66.0,58.3,57.7,36.2,33.3,29.8,22.7,21.7.HRMS(ESI)calculated for C14H23NNaO3S+[M+Na]+:308.1291,found 308.1290.
实例30:化合物30的合成
使用化合物5操作步骤,在50℃下,原料2(0.10g,0.37mmol)与亲电试剂碘丁烷反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物30(109mg,产率:90%):[α]D 23=-48.49(c 0.25,CHCl3).IR(KBr)νmax:2962,2927,2858,1732,1641,1457,1261,1090,1021,801cm-1.1H NMR(400MHz,CDCl3)δ5.87(ddd,J=22.8,11.0,5.8Hz,1H),5.26(dd,J=31.4,13.8Hz,2H),4.56(m,2H),3.13(ddd,J=19.5,8.5,5.9Hz,1H),2.65(dt,J=19.4,7.9Hz,1H),2.36(dt,J=12.7,6.2Hz,1H),2.16–1.78(m,4H),1.76–1.68(m,1H),1.58(dd,J=13.2,4.2Hz,1H),1.34–1.26(m,2H),1.24(d,J=5.5Hz,9H),0.96(dd,J=14.6,7.1Hz,1H),0.88(t,J=6.9Hz,3H).13C NMR(100MHz,CDCl3)δ189.0,172.4,131.9,118.8,66.0,62.0,58.2,35.3,33.2,32.6,27.3,23.9,23.3,22.8,14.1.HRMS(ESI)calculatedfor C17H29NNaO3S+[M+Na]+:350.1760,found 350.1757.
实例31:化合物31的合成
使用化合物5操作步骤,在50℃下,原料2(0.10g,0.37mmol)与亲电试剂1-溴代异戊烷反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物31(116mg,产率:92%):[α]D 23=-78.36(c 0.4,CHCl3).IR(KBr)νmax:2958,2926,2866,1732,1640,1461,1364,1261,1150,1087,1022,803cm-1.1H NMR(400MHz,CDCl3)δ5.88(ddd,J=22.8,11.0,5.8Hz,1H),5.35–5.20(m,2H),4.56(d,J=5.7Hz,2H),3.15(ddd,J=19.5,8.8,5.7Hz,1H),2.65(dt,J=19.4,8.0Hz,1H),2.39–2.31(m,1H),2.05–1.83(m,3H),1.73–1.61(m,2H),1.53–1.40(m,2H),1.24(s,9H),1.13–1.03(m,1H),0.88(dd,J=6.5,4.9Hz,6H).13C NMR(100MHz,CDCl3)δ189.0,172.4,131.9,118.8,66.0,62.0,58.2,34.1,33.4,33.2,32.6,29.9,28.6,22.8,22.7,22.6.HRMS(ESI)calculated for C18H31NNaO3S+[M+Na]+:364.1917,found 364.1913.
实例32:化合物32的合成
使用化合物5操作步骤,在50℃下,原料2(0.10g,0.37mmol)与亲电试剂1-溴-3-氯丙烷反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到浅黄色油状产物32(118mg,产率:92%):[α]D 23=-74.78(c 0.7,CHCl3).IR(KBr)νmax:2962,2926,2859,1732,1650,1455,1281,1088,1019,801cm-1.1H NMR(400MHz,CDCl3)δ5.88(ddd,J=22.8,11.0,5.8Hz,1H),5.28(dd,J=28.1,13.8Hz,2H),4.57(d,J=5.7Hz,2H),3.64–3.35(m,2H),3.20–3.12(m,1H),2.70(dt,J=19.5,7.9Hz,1H),2.36(dt,J=11.2,6.0Hz,1H),2.17–2.04(m,1H),2.02–1.84(m,3H),1.82–1.68(m,3H),1.24(s,9H).13C NMR(100MHz,CDCl3)δ188.2,172.0,131.6,119.0,66.0,61.2,58.2,45.1,32.9,32.9,32.8,28.3,22.6.HRMS(ESI)calculated forC16H26ClNNaO3S+[M+Na]+:370.1214,found 370.1217.
实例33:化合物33的合成
使用化合物5操作步骤,原料3(0.10g,0.35mmol)与亲电试剂苄基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物33(98mg,产率:75%):[α]D 20=-190.84(c 0.5,CHCl3).IR(KBr)νmax:2928,2865,1739,1630,1453,1390,1260,1181,1079,804,742,702cm-1.1H NMR(400MHz,CDCl3)δ7.23(dd,J=8.4,5.9Hz,3H),7.05(dd,J=7.6,1.6Hz,2H),5.92–5.82(m,1H),5.29(ddd,J=13.8,11.5,1.3Hz,2H),4.58(dd,J=6.0,1.1Hz,2H),3.80–3.71(m,1H),3.36(d,J=13.8Hz,1H),2.93(d,J=13.8Hz,1H),2.37–2.30(m,1H),2.19(ddd,J=14.2,12.4,5.1Hz,1H),1.91–1.83(m,1H),1.71–1.62(m,2H),1.55–1.40(m,2H),1.32(s,9H).13C NMR(100MHz,CDCl3)δ183.6,171.4,136.8,131.6,130.4,128.2,126.9,119.5,66.0,60.2,58.3,42.2,35.5,32.4,27.4,22.9,22.3.HRMS(ESI)calculated for C21H29NNaO3S+[M+Na]+:398.1760,found 398.1757.
实例34:化合物34的合成
使用化合物5操作步骤,原料3(0.10g,0.35mmol)与亲电试剂烯丙基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=8:1)得到无色油状产物34(91mg,产率:80%):[α]D 20=-186.03(c 0.4,CHCl3).IR(KBr)νmax:2961,2929,2865,1737,1630,1416,1261,1207,1083,1021,918,802cm-1.1H NMR(400MHz,CDCl3)δ5.92–5.83(m,1H),5.75(ddd,J=23.1,15.5,7.4Hz,1H),5.28(dd,J=34.0,13.8Hz,2H),5.10–5.01(m,2H),4.60(d,J=5.9Hz,2H),3.62–3.52(m,1H),2.67(dd,J=14.0,7.0Hz,1H),2.49–2.31(m,3H),1.86(dd,J=11.8,5.2Hz,1H),1.72–1.62(m,2H),1.57–1.40(m,2H),1.27(s,9H).13C NMR(101MHz,CDCl3)δ183.9,172.1,133.6,131.8,119.2,118.6,66.0,59.2,57.9,40.5,35.7,32.3,27.3,22.8,22.3.HRMS(ESI)calculated for C17H27NNaO3S+[M+Na]+:348.1604,found 348.1600.
实例35:化合物35的合成
使用化合物5操作步骤,在50℃下,原料35(0.10g,0.35mmol)与亲电试剂碘甲烷反应。粗品用柱层析分离(石油醚:乙酸乙酯=10:1)得到无色油状产物7c(68mg,产率:65%):[α]D 27=-57.388(c 0.2,CHCl3).IR(KBr)νmax:2962,2949,1736,1630,1423,1261,1209,1183,1031,802cm-1.1H NMR(400MHz,CDCl3)δ5.94–5.83(m,1H),5.28(dd,J=32.6,14.1Hz,2H),4.61(d,J=5.6Hz,2H),3.57(d,J=14.6Hz,1H),2.61–2.29(m,2H),1.88(s,1H),1.74–1.59(m,2H),1.53–1.41(m,2H),1.35(s,3H),1.26(s,9H).13C NMR(100MHz,CDCl3)δ184.4,173.7,131.8,119.0,66.0,58.0,55.7,38.5,31.8,27.3,23.4,22.8,22.6.HRMS(ESI)calculated for C15H25NNaO3S+[M+Na]+:322.1447,found 322.1444.
实例36:化合物36的合成
使用化合物5操作步骤,原料4(0.10g,0.32mmol)与亲电试剂苄基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=9:1)得到无色油状产物36(116mg,产率:90%):[α]D 20=-315.66(c 0.5,CHCl3).IR(KBr)νmax:2959,2926,2857,1738,1619,1465,1454,1361,1261,1173,1089,1078,1017,801,701,678cm-1.1H NMR(400MHz,CDCl3)δ7.23(dd,J=10.0,7.1Hz,3H),7.07–7.03(m,2H),5.87(ddt,J=16.6,10.4,6.0Hz,1H),5.35–5.24(m,2H),4.61(dd,J=12.9,5.9Hz,1H),4.54(dd,J=12.9,6.1Hz,1H),3.46–3.34(m,2H),2.99(d,J=14.1Hz,1H),2.29–2.07(m,3H),1.84–1.77(m,2H),1.73(m,2H),1.55(m,1H),1.47–1.40(m,1H),1.35(s,9H),1.26(m,2H).13C NMR(101MHz,CDCl3)δ184.7,172.0,137.6,131.6,130.0,128.4,126.9,119.5,66.2,63.1,58.7,38.2,30.7,29.8,27.1,26.0,25.3,25.2,24.2,23.2.HRMS(ESI)calculated for C23H33NNaO3S+[M+Na]+:426.2073,found 426.2077.
实例37:化合物37的合成
使用化合物5操作步骤,原料4(0.10g,0.32mmol)与亲电试剂烯丙基溴反应。粗品用柱层析分离(石油醚:乙酸乙酯=9:1)得到无色油状产物37(102mg,产率:90%):[α]D 20=-335.32(c 1.0,CHCl3).IR(KBr)νmax:2927,2861,1734,1616,1460,1361,1191,1081,991,919,798,753,639cm-1.1H NMR(400MHz,CDCl3)δ5.90–5.79(m,1H),5.73–5.62(m,1H),5.26(dd,J=29.9,13.8Hz,2H),5.13–5.05(m,2H),4.56(d,J=5.5Hz,2H),3.39(dt,J=12.7,4.4Hz,1H),2.86(dd,J=14.4,6.2Hz,1H),2.46–2.33(m,2H),2.25(td,J=12.4,3.4Hz,1H),2.07–1.93(m,2H),1.86–1.67(m,3H),1.59–1.52(m,1H),1.43(m,2H),1.31(s,9H),1.14–1.07(m,1H).13C NMR(100MHz,CDCl3)δ185.1,172.1,134.2,131.7,119.2,118.5,66.2,61.5,58.5,36.9,30.4,27.3,26.8,25.3,24.9,23.1,23.1.HRMS(ESI)calculatedfor C19H31NNaO3S+[M+Na]+:376.1917,found376.1913.
实例38:化合物38的合成
使用化合物5操作步骤,在50℃下,原料4(0.10g,0.32mmol)与亲电试剂碘丁烷反应。粗品用柱层析分离(石油醚:乙酸乙酯=9:1)得到无色油状产物38(106mg,产率:90%):[α]D 26=-102.49(c 0.4,CHCl3).IR(KBr)νmax:2960,2927,2859,1734,1649,1617,1466,1261,1190,1081,1021,802cm-1.1H NMR(400MHz,CDCl3)δ5.84(ddt,J=16.3,10.4,5.9Hz,1H),5.25(ddd,J=13.8,11.5,1.3Hz,2H),4.55(d,J=5.9Hz,2H),3.44–3.28(m,1H),2.36(ddd,J=15.5,11.0,4.7Hz,1H),2.25(td,J=12.4,3.5Hz,1H),2.12–1.94(m,3H),1.86–1.61(m,4H),1.53–1.46(m,2H),1.36(dd,J=18.2,10.0Hz,2H),1.32–1.27(m,9H),1.24(dd,J=11.7,4.9Hz,2H),1.13–1.00(m,2H),0.89(t,J=7.2Hz,3H).13C NMR(101MHz,CDCl3)δ185.7,172.8,131.8,119.0,65.9,61.4,58.5,32.1,30.4,27.4,27.0,26.9,25.3,24.9,23.4,23.3,23.1,14.1.HRMS(ESI)calculated for C20H35NNaO3S+[M+Na]+:392.2230,found 392.2227.
TGF-β1细胞因子被认为是关键促纤维化因子,因此就TGF-β1/Smad3信号通路建立了细胞筛选体系。该体系使用了在Luciferase报告基因的基础上增加了TGF-β1下游Smad3转录因子保守结合的启动子序列CAGA的CAGA-NIH3T3稳转细胞系,这个细胞系对TGF-β1的刺激具有超敏特性。当有TGF-β1刺激CAGA-NIH 3T3细胞时,可诱导Smad转录因子活化入核结合启动子序列CAGA,从而诱导CAGA box后面荧光素酶基因序列转录翻译出荧光素酶,而荧光素酶可以氧化荧光素,且在这一过程中会发出生物荧光,从而可以根据荧光的强弱来得知荧光素酶的表达情况,荧光素酶的表达量与转录因子Smad的作用强度成正比。这个体系就可以检测化合物是否对TGF-βSmad这一信号通路有抑制作用。
为了更好理解本发明,下面用化合物1-38进行实验,说明这些化合物在药学领域存在潜在的用途。必须说明,本发明的药理实施例是用于说明本发明而不是对本发明的限制。根据本发明的实质对本发明进行的简单改进都属于本发明的保护范围。
实验步骤
荧光素酶报告基因检测
首先收集对数生长期的CACG-NIH3T3细胞,以0.5×105个/ml的细胞悬液100μL接种于96孔板中,培养过夜。待细胞长至约70%时撤血清,经24h培养后实验组分别加入各化合物进行加药检测,并设有空白对照组和不加药的TGF-β1刺激组,继续放至培养箱中培养18h后进行细胞裂解并加底物检测荧光值的变化情况。所有的实验组均有三次重复。
测试结果
如表1所示。
表1
以上对本发明的具体实例进行了详细描述,但其只是作为范例,本发明并不限制于以上描述的具体实例。对于本领域技术人员而言,任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所做的均等变换和修改,都应涵盖在本发明的范畴内。
Claims (10)
1.一种构建手性亚磺酰亚胺α位手性四级碳的烷基化方法,其特征在于,其合成路线如下:
并且,所述方法包括以下步骤:
(1)以化合物A1为起始原料,与手性亚磺酰胺缩合,制得中间体A2;
(2)所述中间体A2与导向基团DG的供体反应制得中间体A3;
(3)所述中间体A3经烷基化反应,即制得α位具有手性四级碳的手性亚磺酰亚胺A。
2.根据权利要求1所述的方法,其特征在于:
步骤(1)中,将化合物A1溶于四氢呋喃中,依次加入R-叔丁基亚磺酰胺、四异丙醇钛反应,制得中间体A2;
步骤(2)中将所述中间体A2溶于四氢呋喃中,冷却至-78℃,加入碱B1反应,再加入导向基团DG的供体,-78℃下搅拌反应,制得中间体A3;
步骤(3)中将所述中间体A3溶于四氢呋喃中,冷却至0℃,加入碱B2反应,再加入亲电试剂即R-X反应,制得目标产物A。
3.根据权利要求2所述的方法,其特征在于:步骤(1)中将化合物A1溶于四氢呋喃中,在室温下依次加入R-叔丁基亚磺酰胺、四异丙醇钛,加热至40-70℃反应6-12小时,制得中间体A2。
4.根据权利要求2所述的方法,其特征在于:步骤(2)中将所述中间体A2溶于四氢呋喃中,在低温反应仪下冷却至-78℃,加入碱B1反应1小时,再缓慢滴加导向基团DG的供体,-78℃下搅拌反应2-5小时,制得中间体A3;
优选的,所述碱B1为NaHMDS、KHMDS或LiHMDS。
5.根据权利要求2所述的方法,其特征在于:步骤(3)中将所述中间体A3溶于四氢呋喃中,冷却至0℃,加入碱B2反应15分钟,0℃下搅拌反应15-60分钟,再加入亲电试剂即R-X,反应5-60分钟后移至20-60℃下反应8-24小时,制得目标产物A;
优选的,所述碱B2可优选为NaHMDS、KHMDS、LiHMDS。
6.根据权利要求2所述的方法,其特征在于:制得中间体A2、制得中间体A3及制得目标产物A前需要分别进行后处理,所述的后处理均为本领域技术人员根据本步反应条件做出的合适的后处理,这些后处理能够在除去杂质与溶剂并在一定程度上保证获得纯净的产物;
优选的,步骤(1)中制得中间体A2前需要进行的后处理指的是:反应完毕后,向反应液中加入水猝灭,过滤除去沉淀,并用乙酸乙酯洗涤沉淀,所得有机相经无水硫酸钠干燥,抽滤、浓缩后用快速柱层析分离,即得中间体A2;
优选的,步骤(2)中的制得中间体A3前需要进行的后处理指的是:反应完毕后,向反应液中加入饱和氯化铵溶液猝灭,并用乙酸乙酯萃取3次,合并有机相经无水硫酸钠干燥,抽滤、浓缩后用快速柱层析分离,即得中间体A3;
优选的,步骤(3)中制得目标产物A前需要进行的后处理指的是:反应完毕后,向反应液中加入饱和氯化铵溶液猝灭,并用乙酸乙酯萃取3次,合并有机相经无水硫酸钠干燥,抽滤、浓缩后用快速柱层析分离,即得目标产物A。
7.一种α位具有手性四级碳的手性亚磺酰亚胺化合物,其特征在于,所述化合物结构通式为A,
导向基团DG为吸电子基团;
R为亲电取代基;
R1R2为碳环或杂环,或者R1和R2各自独立地选自:H,烷基,烯基,炔基,烷氧基,芳烃基烷氧基,芳烃基,杂环芳烃基;
化合物中叔丁基(t-Bu)可以是2,4,6-三甲基苯基(Mes)、甲基苯基(Tol)、苯基(Ph)或异丙基(i-pr);
亚磺酰基的构型是R或S。
8.根据权利要求7所述的化合物,其特征在于:化合物A的结构式为I或II,
其中,所述结构通式I特征在于:
(I1)导向基团DG为酯基、酮基、酰胺基、氰基或硝基;
(I2)亲电取代基R为烷基芳基、烷基烯基、烷基炔基、烷基、F、CF3、Br、Cl或Michael受体;
(I3)B环为C4-C30的碳环或碳杂环;优选的,碳杂环为含氮、硫、氧和/或磷的碳杂环;
(I4)化合物中叔丁基(t-Bu)可以是2,4,6-三甲基苯基(Mes)、甲基苯基(Tol)、苯基(Ph)或异丙基(i-pr),亚磺酰基的构型可以是R或S;
并且,所述结构通式II特征在于:
(II1)导向基团DG为酯基、酮基、酰胺基、氰基或硝基;
(II2)亲电取代基R为;烷基芳基、烷基烯基、烷基炔基、烷基、F、CF3、Br、Cl或Michael受体;
(II3)R1和R2各自独立地选自:H,C1-C30的链烷基,C3-C30的环丙烷基,C2-C30的链烯基,C3-C30的环烯基,C2-C30的链炔基,C1-C30的烷氧基,C7-C30芳烃基烷氧基,C6-C30的芳烃基,或C4-C30的杂环芳烃基;
(II4)化合物中叔丁基(t-Bu)可以是2,4,6-三甲基苯基(Mes)、甲基苯基(Tol)、苯基(Ph)或异丙基(i-pr),亚磺酰基的构型可以是R或S;
优选的,导向基团DG为:烯丙氧羰基、苄氧羰基、异丙氧羰基或甲氧羰基;
优选的,取代基R为苄基、取代苄基、烯丙基、取代烯丙基、炔丙基、取代炔丙基或饱和烷烃;
优选的,所述化合物A由权利要求1-5任一项所述的方法制得。
9.一种权利要求7或8所述的化合物A在制备抑制器官纤维化药物中的应用。
10.一种药物组合物,其特征在于:其含有效治疗量的权利要求7或8所述的化合物A,以及药学上接受的辅料;
优选的,所述药物组合物为片剂、胶囊剂、气雾剂、分散片、口服液、栓剂、滴丸剂、大输液、小针、冻干粉针、软膏或搽剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810111787.7A CN108129367B (zh) | 2018-02-05 | 2018-02-05 | 一种构建手性亚磺酰亚胺α位手性四级碳的构建方法及其产品与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810111787.7A CN108129367B (zh) | 2018-02-05 | 2018-02-05 | 一种构建手性亚磺酰亚胺α位手性四级碳的构建方法及其产品与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108129367A true CN108129367A (zh) | 2018-06-08 |
CN108129367B CN108129367B (zh) | 2020-10-02 |
Family
ID=62430523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810111787.7A Active CN108129367B (zh) | 2018-02-05 | 2018-02-05 | 一种构建手性亚磺酰亚胺α位手性四级碳的构建方法及其产品与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108129367B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022226812A1 (zh) * | 2021-04-27 | 2022-11-03 | 苏州弘森药业股份有限公司 | 一种使用手性辅基制备左旋特布他林的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103159652A (zh) * | 2011-12-19 | 2013-06-19 | 天津市国际生物医药联合研究院 | 亚磺酰胺类化合物的制备及其应用 |
CN104744394A (zh) * | 2015-02-16 | 2015-07-01 | 中国农业大学 | 一种不对称合成含三氟甲基手性季碳化合物的方法 |
CN107011270A (zh) * | 2010-11-16 | 2017-08-04 | 阿塞蒂隆制药公司 | 作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法 |
CN107188874A (zh) * | 2017-04-19 | 2017-09-22 | 浙江工业大学 | 一种手性季碳化合物的合成方法 |
-
2018
- 2018-02-05 CN CN201810111787.7A patent/CN108129367B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107011270A (zh) * | 2010-11-16 | 2017-08-04 | 阿塞蒂隆制药公司 | 作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法 |
CN103159652A (zh) * | 2011-12-19 | 2013-06-19 | 天津市国际生物医药联合研究院 | 亚磺酰胺类化合物的制备及其应用 |
CN104744394A (zh) * | 2015-02-16 | 2015-07-01 | 中国农业大学 | 一种不对称合成含三氟甲基手性季碳化合物的方法 |
CN107188874A (zh) * | 2017-04-19 | 2017-09-22 | 浙江工业大学 | 一种手性季碳化合物的合成方法 |
Non-Patent Citations (2)
Title |
---|
CHEN, SHUFENG等: "Preparation of cyclic N-tert-butylsulfonyl enamines by Rh(II)-mediated ring expansion of α-diazo esters", 《SYNTHESIS》 * |
DAVID GUIJARRO等: "Synthesis of Nitrogenated Heterocycles by Asymmetric Transfer Hydrogenation of N ‑ (tert -Butylsulfinyl)haloimines", 《J. ORG. CHEM.》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022226812A1 (zh) * | 2021-04-27 | 2022-11-03 | 苏州弘森药业股份有限公司 | 一种使用手性辅基制备左旋特布他林的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108129367B (zh) | 2020-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110372598A (zh) | 一种合成氘代酰胺及氘代磺酰胺的新方法 | |
WO2019120210A1 (zh) | 一类苯并呋喃及Coumestans衍生物及其制备方法和应用 | |
CN115626913B (zh) | 一种制备瑞马唑仑关键中间体的方法 | |
SK7602002A3 (en) | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | |
CN106279104B (zh) | 一种制备琥珀酸曲格列汀的工艺改进方法 | |
CN106456645B (zh) | 用于放射性标记的方法和试剂 | |
CN106008385B (zh) | 一种帕瑞昔布钠的合成方法 | |
CN112062712A (zh) | 一种2-(5-溴-3-甲基吡啶-2-基)乙酸盐酸盐的制备方法 | |
CN108129367A (zh) | 一种构建手性亚磺酰亚胺α位手性四级碳的构建方法及其产品与应用 | |
KR0163441B1 (ko) | 트리시클릭[6,5,5]/[6,6,5]-융합 옥사졸리디논 항균제 | |
CN105017147B (zh) | 一种回收和利用Bedaquiline立体化学异构体的方法 | |
WO2009074020A9 (zh) | α-氨基-N-取代酰胺化合物、包含该化合物的药物组合物及其用途 | |
CN102887856B (zh) | 一种合成布南色林的方法 | |
CN103012350A (zh) | 苯并吡喃类手性化合物的合成方法 | |
CN108503609B (zh) | 一种制备光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的方法 | |
CN112500347B (zh) | 一种苯并氮杂七元环化合物、其制备方法及用途 | |
CN115010638B (zh) | 一种奈玛特韦中间体的合成方法 | |
CN101941943A (zh) | 2-氯-3-氰基吡啶的合成方法 | |
CN107686456B (zh) | 一种喹喏酮关键中间体乙酯胺化物及其制备方法和应用 | |
CN117242061A (zh) | 用于治疗艰难梭菌的二氮杂卓衍生物 | |
Chen et al. | Formal synthesis of (+)-tashiromine and study toward the total synthesis of (+)-stemoamide | |
CN112812048B (zh) | 一种钠离子通道阻滞剂cnv1014802盐酸盐形态的制备方法 | |
CN115466259B (zh) | 一种kras g12c抑制剂索托拉西布的制备方法 | |
CN114773237B (zh) | 一类含磺酸酯结构的新型苯丙烯基羟肟酸衍生物及其制备方法和应用 | |
CN103664917B (zh) | 一种2-取代噁唑啉或2-取代噁嗪的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |